Anti-CD27 may also enhance the efficacy of other ADCP-dependent tumour-targeting mAbs in other cancers, such as anti-EGFR in head and neck squamous cell carcinoma and anti-GD2 in neuroblastoma. Here, EGFR is linked to neoplasm.